WIREs Mech Dis. 2026 Nov-Dec;18(6):pii: e70019. [Epub ahead of print]18(6):
Conventional tissue biopsy remains the clinical standard for diagnosing many cancers, but it provides only a spatially restricted and temporally limited view of disease. Cell-free DNA (cfDNA) is a minimally invasive source of molecular information that may reflect temporal changes in tissue injury, clonal evolution, and epigenetic remodeling. This review distinguishes early tumorigenesis, premalignant states, preinvasive disease, and early-stage cancer, and examines how mutational profiling, fragmentomics, DNA methylation, and extracellular vesicles can be used to investigate molecular events across this continuum. The conceptual contribution is to frame cfDNA as a longitudinal readout of somatic evolution rather than solely a one-time cancer detection assay, while distinguishing direct measurements from computational inferences. We also discuss clonal hematopoiesis, signal dilution, the lack of validated reference standards, and the mismatch between dynamic tumor evolution and static biomarker assays. Longitudinal and multimodal analyses are biologically promising; however, current evidence does not yet demonstrate that cfDNA can directly or continuously monitor malignant transformation. In the near term, its value may lie primarily in risk stratification, mechanistic research, and rigorously validated surveillance of selected high-risk populations.
Keywords: cell‐free DNA; early cancer detection; fragmentomics; multiomics integration; tumorigenesis